Suggestions
Mark Coles
Kennedy Professor of Immunology, Kennedy Institute of Rheumatology, Founding Fellow and Cellular Life Theme Lead Reuben College, University of Oxford
Mark Coles is a prominent immunologist and the co-founder of Mestag Therapeutics, a biotech company established in 2020 that focuses on developing precision medicines targeting fibroblast subpopulations involved in inflammatory diseases and cancer. He holds the position of Kennedy Professor of Immunology at the Kennedy Institute of Rheumatology, part of the University of Oxford.123
Background and Contributions
- Academic Role: Mark Coles is affiliated with the Nuffield Department of Orthopaedics and Musculoskeletal Sciences at the University of Oxford, where he conducts research on immune function and human therapeutics.3
- Mestag Therapeutics: The company aims to create innovative therapies that leverage insights into fibroblast-immune cell interactions. This approach is particularly relevant for patients who do not respond to conventional treatments like checkpoint inhibitors.12
Research Focus
Coles' research primarily revolves around understanding how fibroblasts influence immune responses, which is crucial for developing new treatments for various diseases, including cancer and autoimmune disorders.14 His work has contributed to advancing a pipeline of first-in-class therapeutics aimed at improving patient outcomes in these challenging areas.2
Through his leadership at Mestag Therapeutics, Coles is actively involved in translating complex scientific insights into practical therapeutic applications, underscoring his commitment to addressing unmet medical needs in immunology and oncology.12
